Treatment of Bacterial Vaginosis
Information source: University of Alabama at Birmingham
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Vaginosis
Intervention: metronidazole and azithromycin (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: University of Alabama at Birmingham Official(s) and/or principal investigator(s): Jane Schwebke, MD, Principal Investigator, Affiliation: University of Alabama at Birmingham
Summary
We are trying to determine if longer duration of therapy with metronidazole or combination
therapy of metronidazole plus azithromycin results in better cure rates for BV
Clinical Details
Official title: Therapy and Prevention for Sexually Associated Bacterial Vaginosis
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Primary outcome: cure of bacterial vaginosis
Detailed description:
Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the
U. S. and has been associated with complications including preterm delivery of infants, pelvic
inflammatory disease (PID), urinary tract infections (UTI) and acquisition/transmission of
sexually transmitted diseases (STDs) including human immunodeficiency virus (HIV). Control
of BV has been advocated for decreasing the prevalence of these complications. The etiology
of BV remains unknown and the current treatment regimens are inadequate in terms of initial
cure and recurrence rates. Further, half of all women who meet the clinical diagnostic
criteria for BV are asymptomatic and treatment of these women remains controversial. More
detailed characterization of the origins, natural history and response to therapy would
supply data to guide control efforts. We will approach these problems through a multifaceted
interdisciplinary evaluation of women with and without BV.
The specific aims {and hypotheses} of this project are:
1. To conduct studies to determine optimal agents and duration of therapy for BV
{Hypothesis: Longer duration of therapy and combination therapy will result in higher
cure rates and lower recurrence rates of BV; response to therapy differs between women
with asymptomatic BV and symptomatic BV}
2. To examine the role of condoms in the prevention of BV {Hypothesis: BV is a sexually
transmitted infection, thus recurrence rates of BV will be lower among women with higher
condom usage rates}
3. To further explore the role of Mobiluncus spp., organisms strongly associated with the
syndrome, by utilizing specimens derived from the above studies.
{Hypothesis: Mobiluncus is involved in the pathogenesis of BV at least in a subset of women,
and the persistence of this organism is associated with lack of cure and recurrence of BV}
Eligibility
Minimum age: 16 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria: symptomatic bacterial vaginosis
-
Exclusion Criteria:
- pregnancy, other genital infections
Locations and Contacts
Jefferson County Department of Health STD Clinic, Birmingham, Alabama 35294, United States
Additional Information
Starting date: July 2002
Ending date: May 2005
Last updated: December 14, 2007
|